{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:55:26Z","timestamp":1789077326051,"version":"build-2803163510"},"reference-count":14,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["analyticalsciencejournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Drug Testing and Analysis"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>In recent years, a scenario involving milk contamination by biotransformation products of the veterinary drug Emidonol has received widespread publicity. Emidonol is intended for use in cattle under pathological conditions accompanied by hypoxia. The drug dissociates into two antihypoxants\u2014meldonium, a metabolic modulator prohibited in sports, and emoxypine, which also has antioxidant properties. A small\u2010scale pilot study involved three volunteers consuming a single 900\u2010mL dose of unpasteurized cow's milk collected on the last (15th) day of treatment with the drug. The mean estimated urinary concentration of emoxypine peaked between 7\u2010 and 8.5\u2010h postadministration (1360\u2009\u00b1\u2009240\u2009ng\/mL), elimination time being approximately 50\u201354\u2009h. The mean estimated urinary concentration of meldonium peaked between 5.8\u2010 and 9.0\u2010h postadministration and was 322\u2009\u00b1\u200968\u2009ng\/mL, elimination time being approximately 35\u201345\u2009h. The simultaneous presence of emoxypine and meldonium in urine samples may be indicative of the consumption of Emidonol\u2010contaminated milk, which may facilitate the identification of cases of unintended doping in sport.<\/jats:p>","DOI":"10.1002\/dta.70031","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:33:42Z","timestamp":1769733222000},"page":"414-418","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Emoxypine as a Potential Marker for Identifying Possible Cases of Unintended Meldonium Doping in Sports"],"prefix":"10.1002","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-0582","authenticated-orcid":false,"given":"Pavel\u00a0V.","family":"Postnikov","sequence":"first","affiliation":[{"name":"National Anti\u2010Doping Laboratory (Institute) Lomonosov Moscow State University (NADL MSU)  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3582-0012","authenticated-orcid":false,"given":"Yulia\u00a0A.","family":"Efimova","sequence":"additional","affiliation":[{"name":"Institute of Fine Chemical Technologies Russian Technological University (RTU\u2010MIREA)  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0588-6870","authenticated-orcid":false,"given":"Igor\u00a0A.","family":"Rodin","sequence":"additional","affiliation":[{"name":"Institute of Fine Chemical Technologies Russian Technological University (RTU\u2010MIREA)  Moscow Russia"},{"name":"Chemical Faculty Lomonosov Moscow State University  Moscow Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"issue":"17","key":"e_1_2_7_2_1","first-page":"13","article-title":"Ichthyotoxicological Properties of Emidonol 20%. Pharmacodynamics and Clinical Use of Antihypoxants (In Russ.)","volume":"1","author":"Vasiliev A. A.","year":"2015","journal-title":"Bulletin of the Agro\u2010Industrial Complex of Stavropol"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2017"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3145"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2020"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.33029\/0042\u20108833\u20102024\u201093\u20105\u201094\u2010103"},{"key":"e_1_2_7_7_1","unstructured":"World Anti\u2010Doping Agency. \u201cProhibited List 2026 \u201d accessed 2026\u201001\u201012 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2025\u201009\/2026list_en_final_clean_september_2025.pdf."},{"key":"e_1_2_7_8_1","unstructured":"World Anti\u2010Doping Agency \u201cMonitoring Program 2026 \u201d accessed 2026\u201001\u201012 https:\/\/hns.family\/files\/documents\/32181\/WADA%202026%20Monitoring%20Program.pdf."},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202512505122"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.3655"},{"issue":"2","key":"e_1_2_7_11_1","first-page":"23","article-title":"Excretion Kinetics of Mexidol and Its Glucuronide\u2010Conjugated Metabolite in Volunteers From Kazakh and Russian Populations [in Russ.]","volume":"1","author":"Sariev A. K.","year":"2005","journal-title":"\u0421linical Pharmacokinetics"},{"issue":"5","key":"e_1_2_7_12_1","first-page":"42","article-title":"The Kinetics of the Urinary Excretion of Mexidol and Its Glucuronate Conjugate in Patients. [In Russia]","volume":"62","author":"Sariev A. K.","year":"1999","journal-title":"Eksperimental'naia i Klinicheskaia Farmakologiia"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.32362\/2410\u20106593\u20102025\u201020\u20104\u2010382\u2010398"},{"key":"e_1_2_7_14_1","unstructured":"World Anti\u2010Doping Agency \u201cTD2022MRPL \u201d accessed 2026\u201001\u201012 https:\/\/www.wada\u2010ama.org\/sites\/default\/files\/2022\u201001\/td2022mrpl_v1.1_eng_0.pdf."},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/dta.2521"}],"container-title":["Drug Testing and Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70031","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/dta.70031","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dta.70031","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:21:13Z","timestamp":1773386473000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/dta.70031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":14,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/dta.70031"],"URL":"https:\/\/doi.org\/10.1002\/dta.70031","archive":["Portico"],"relation":{},"ISSN":["1942-7603","1942-7611"],"issn-type":[{"value":"1942-7603","type":"print"},{"value":"1942-7611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"assertion":[{"value":"2025-12-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}